← Back to Search

Tyrosine Kinase Inhibitor

Erdafitinib for Cancer

Phase 2

Waitlist Available

Led By Alice Lee

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must not have received prior exposure to erdafitinib or another FGFR inhibitor such as (but not limited to) AZD4547, BGJ398, BAY1163877, LY2874455

Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =/< 135 U/L; (for the purpose of this study, the ULN for SGPT is 45 U/L) (performed within 7 days prior to enrollment)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial uses erdafitinib to treat patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread and come back or don't respond to treatment with FGFR mutations.

Who is the study for?

This trial is for children and young adults aged 12 months to 21 years with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have FGFR mutations. Participants must be able to swallow tablets, have not been treated with erdafitinib before, and meet specific health criteria like normal bilirubin levels and kidney function.Check my eligibility

What is being tested?

The study tests the effectiveness of erdafitinib in patients whose cancer has returned or is resistant to treatment. It aims to see if this drug can stop cancer growth by blocking enzymes needed for cell growth. The trial includes imaging tests like X-rays and MRIs as well as biospecimen collection.See study design

What are the potential side effects?

While the document does not list specific side effects of erdafitinib, similar medications often cause diarrhea, dry mouth, nail changes, low appetite, altered taste sensation, hair loss and may affect liver function which will be monitored during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have never taken erdafitinib or similar FGFR inhibitor drugs.

Select...

My liver enzyme (ALT) level is within the required range for the study.

Select...

My kidney function tests are within the normal range.

Select...

I can swallow pills without any issues.

Select...

My body surface area is at least 0.53 square meters.

Select...

I have received external beam radiation therapy.

Select...

I have received radiopharmaceutical therapy.

Select...

I have received a stem cell infusion, with or without total body irradiation.

Select...

I am enrolled in APEC1621SC and assigned to MATCH in APEC1621B due to an actionable mutation.

Select...

I am between 12 and 21 years old.

Select...

My solid tumor cancer has not spread to my bone marrow.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Response rate

Secondary outcome measures

Incidence of adverse events

Pharmacokinetic (PK) parameters

Progression free survival (PFS)

Other outcome measures

Changes in tumor genomic profile

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (erdafitinib)Experimental Treatment11 Interventions

Patients receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Computed Tomography

2017

Completed Phase 2

~2720

Biospecimen Collection

2004

Completed Phase 2

~1730